Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 11/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | SLC8A1 | P32418 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21536066 | 0.93 | DUT (0.40) | DUTKAT6AALDH1A1DDB1CRBN | |
| SCHEMBL21536680 | 0.86 | DUT (0.40) | DUTKAT6AALDH1A1LMNA | |
| SCHEMBL21536061 | 0.85 | DUT (0.41) | DUTKAT6ADDB1CRBN | |
| SCHEMBL21536732 | 0.85 | DUT (0.43) | DUTSLC8A1ALDH1A1 | |
| SCHEMBL21536564 | 0.85 | DUT (0.43) | DUTKAT6AALDH1A1 | |
| SCHEMBL21536675 | 0.85 | DUT (0.43) | DUTKAT6AALDH1A1 | |
| SCHEMBL20189396 | 0.83 | DUT (0.49) | DUTKAT6AALDH1A1 | |
| SCHEMBL21536062 | 0.83 | DUT (0.41) | DUTKAT6AALDH1A1DDB1CRBN | |
| SCHEMBL21536599 | 0.83 | DUT (0.42) | DUTKAT6AALDH1A1DDB1CRBN | |
| SCHEMBL21536735 | 0.83 | DUT (0.42) | DUTKAT6AALDH1A1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | TYMP, DUT, TYMS | DUT 2/4885KAT6A 3297/4885SLC8A1 4416/4885 |
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | DUT 3/4885KAT6A 3309/4885SLC8A1 1968/4885 |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | DPYD, DNPEP, DUT | DUT 3/4885KAT6A 3309/4885SLC8A1 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.